Observational study on the safety and effectiveness of SARS-CoV-2 vaccination in patients with lung cancer
Our real-world data supported the safety and effectiveness of SARS-CoV-2 vaccines in patients with lung cancer. SARS-CoV-2 vaccines protected most of our population from infection, and those infected developed mild-to-moderate disease.
Authors
- Xabier Mielgo-Rubio (ORCID: https://orcid.org/0000-0002-0985-6150)
- Ernest Nadal (ORCID: https://orcid.org/0000-0002-9674-5554)
- María Carmen Riesco Martínez (ORCID: https://orcid.org/0000-0003-0626-0607)
- S. Cerezo (ORCID: https://orcid.org/0009-0002-9093-4837)
- José Manuel Baena (ORCID: https://orcid.org/0000-0002-7199-5186)
- Eider Azcona
- Zara Vidales (ORCID: https://orcid.org/0000-0002-4599-0277)
- M. Antoñanzas (ORCID: https://orcid.org/0000-0002-7434-9059)
- Maria Saigí (ORCID: https://orcid.org/0000-0001-5815-5388)
- José David Cumplido
- Joseph C. González (ORCID: https://orcid.org/0000-0002-3282-0041)
- Anna Estival
- M. Guirado
- Begoña Campos (ORCID: https://orcid.org/0000-0002-8927-9129)
- María Ángeles Sala
- Teresa Morán
- A. Díaz-Serrano
- María Pilar Diz-Taín
Institutions
- Universitat Autònoma de Barcelona (ES)
- Hospital Universitario Insular de Gran Canaria (ES)
- Hospital Clínico San Carlos (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Hospital de Basurto (ES)
- Complejo Hospitalario Universitario de Santiago (ES)
- Hospital Universitario Fundación Alcorcón (ES)
- Institut Català d'Oncologia (ES)
- Hospital Universitario Araba (ES)
- Hospital General Universitario de Elche (ES)
- Hospital General Universitario de Ciudad Real (ES)
- Hospital Virgen de la Concha (ES)
- Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol (ES)
- Hospital de Cruces (ES)
- Hospital Universitario Lucus Augusti (ES)
- Hospital Quirón Torrevieja (ES)
- Hospital Universitari Germans Trias i Pujol (ES)
- Hospital Universitario de León (ES)
Publication Details
- Journal
- ESMO Real World Data and Digital Oncology
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1016/j.esmorw.2025.100125
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Clovis Oncology
- Apollomics
- Daiichi-Sankyo
- PharmaMar